Drug intelligence / Profile preview

MVA-VLP tetravalent vaccine

Development stage: Preclinical
Lead developer: GeoVax Labs
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous, Intradermal, Percutaneous, Oral

Overview

The MVA-VLP tetravalent vaccine is a vaccine candidate developed by GeoVax Labs, Inc. It utilizes a Modified Vaccinia Ankara (MVA) viral vector to deliver Virus-Like Particles (VLPs) designed to elicit an immune response against four hemorrhagic fever viruses: Ebola Zaire, Ebola Sudan, Marburg, and Lassa fever viruses. The vaccine aims to provide broad protection against future outbreaks of these highly pathogenic diseases.

Other names: GeoVax Hemorrhagic Fever VaccineMVA-VLP Hemorrhagic Fever Vaccine

Targets

Marburg virus antigensLassa virus antigensCCHFV antigen (Crimean-Congo hemorrhagic fever virus antigen)Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on MVA-VLP tetravalent vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVA-VLP tetravalent vaccine.

Explore the full profile